Opendata, web and dolomites

PROBIOTEARS SIGNED

Probiotic-based Ophtalmologic treatment for Bacterial and Allergic Conjunctivitis

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 PROBIOTEARS project word cloud

Explore the words cloud of the PROBIOTEARS project. It provides you a very rough idea of what is the project "PROBIOTEARS" about.

million    strain    functional    feasibility    industrial    ebitda    tests    safety    ab    micro    deeper    global    ophthalmologists    innovative    ointments    ocular    fast    generate    validated    protection    ipr    organisms    associations    drops    mainly    inflammatory    intraocular    formula    perform    vivo    pressure    covered    presented    antagonism    treatments    reinforce    antibiotic    strains    animal    histaminic    people    issue    rising    infections    faster    healthy    ready    innovation    anti    microbiota    competitor    solid    supportive    clinical    pathogenic    strategy    probiotics    eye    formulation    suitable    probiotic    resistance    resistances    aligned    trials    pharmaceutical    ingredients    allergic    biotics    galenic    conjunctivitis    bacterial    toxicity    market    drugs    models    avoidance    recurrent    expertise    14m    pathogens    solution    live    stable    1100    scaling    risks    undesired    regulatory    dimension    antihistaminic    broad    vitro    carry    company    probiotears    ophthalmic    health    worldwide    reestablishment    industry   

Project "PROBIOTEARS" data sheet

The following table provides information about the project.

Coordinator
AB BIOTICS SA 

Organization address
address: CALLE PARC DE RECERCA UAB CAMPUS AUB EDIFICIO DESPACHO P2M1 BELLATERRA
city: CERDANYOLA DEL VALLES
postcode: 8193
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Spain [ES]
 Project website http://www.ab-biotics.com/
 Total cost 71˙429 €
 EC max contribution 50˙000 € (70%)
 Programme 1. H2020-EU.3.2.4. (Sustainable and competitive bio-based industries and supporting the development of a European bioeconomy)
2. H2020-EU.3.2.1. (Sustainable agriculture and forestry)
3. H2020-EU.2.3.1. (Mainstreaming SME support, especially through a dedicated instrument)
4. H2020-EU.3.2.2. (Sustainable and competitive agri-food sector for a safe and healthy diet)
 Code Call H2020-SMEINST-1-2016-2017
 Funding Scheme SME-1
 Starting year 2017
 Duration (year-month-day) from 2017-10-01   to  2018-03-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    AB BIOTICS SA ES (CERDANYOLA DEL VALLES) coordinator 50˙000.00

Map

 Project objective

Conjunctivitis is a major health issue affecting more than 1100 million people worldwide. Currently, the market for bacterial & allergic conjunctivitis is mainly covered by antibiotic eye drops and ointments, which have undesired effects in the eye microbiota and contribute to increase the resistances of pathogenic strains. Other treatments such as anti-inflammatory and antihistaminic drugs have also undesired side effects and are not useful as an immediate solution.

AB-BIOTICS, a company with a broad expertise in developing functional ingredients for the pharmaceutical industry, has developed an innovative solution based on the use of probiotics. Probiotics are live micro-organisms allowing a fast and stable reestablishment of a healthy eye microbiota by providing: (1) faster anti-inflammatory and anti-histaminic effects; (2) antagonism to pathogens with no resistance risks; (3) protection against future/recurrent infections; and (4) avoidance of common side effects such as intraocular pressure rising.

The effects of the selected probiotic strains have been validated through functional in vitro and in vivo tests and its safety for ocular application has also been assessed in toxicity trials in animal models. The industrial scaling up of the strain has already been achieved and is now ready for galenic formulation.

In order to determine the key steps to bring PROBIOTEARS to the market within the next 2 years, the objectives of the presented feasibility study are: • Assess clinical ophthalmologists & users associations interest • Determine the most suitable formula for ophthalmic use • Define IPR strategy • Perform a deeper market & competitor analysis • Find key partners to carry out Supportive Clinical Trials in phase 2 • Assess Regulatory Requirements

PROBIOTEARS is a solid high-potential innovation project aligned with AB-BIOTICS’ strategy which is expected to reinforce its European & global dimension, and generate an EBITDA of 2,14M€.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "PROBIOTEARS" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "PROBIOTEARS" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.2.4.;H2020-EU.3.2.1.;H2020-EU.2.3.1.;H2020-EU.3.2.2.)

Stoock (2018)

An Innovative Integrated Field Sensor system providing a precise farming tool to reduce productioncosts and water wastage.

Read More  

INDI (2018)

INDI, world’s first 100% dairy free, soy-free infant-formula.

Read More  

INSYLO (2018)

Disruptive IoT solution for optimising the animal feed supply chain

Read More